<DOC>
	<DOC>NCT01629966</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy, safety and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD)</brief_summary>
	<brief_title>Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Vilazodone Hydrochloride</mesh_term>
	<criteria>Male and female, 18 70 years of age Currently meet the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSMIVTR) criteria for Generalized Anxiety Disorder (GAD) Minimum score of 20 on the Hamilton Rating Scale for Anxiety (HAMA) Women who are pregnant, women who will be breastfeeding during the study and women of childbearing potential who are not practicing a reliable method of birth control Patients with a history of meeting DSMIVTR criteria for Any manic or hypomanic or mixed episode, including bipolar disorder and substanceinduced manic, hypomanic or mixed episode Any depressive episode with psychotic or catatonic features Panic disorder with or without agoraphobia Obsessivecompulsive disorder Schizophrenia, schizoaffective, or other psychotic disorder Bulimia or anorexia nervosa Presence of borderline personality disorder or antisocial personality disorder Mental retardation, dementia, amnesia, or other significant cognitive disorders Patients who are considered a suicide risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Generalized Anxiety Disorder</keyword>
	<keyword>GAD</keyword>
</DOC>